Stockscreener 앱 받기
145.70
3.84%
5.39
시간 외 거래:
145.70
Palvella Therapeutics Inc 주식(PVLA)의 최신 뉴스
PVLAPalvella Therapeutics Inc Volatility & Greeks - Finviz
Price to book forward of Palvella Therapeutics, Inc. – NASDAQ:PVLA - TradingView
Mizuho Securities Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $240 - Moomoo
Palvella Therapeutics Adds Rare Disease Executive Matt Pauls to Board of Directors - citybiz
Palvella Therapeutics, Inc. Files Form 8-K: Key Company Details, Stock Info, and Contact Information (June 2026) - Minichart
Palvella Therapeutics appoints Matt Pauls to board of directors By Investing.com - Investing.com South Africa
Palvella Therapeutics appoints Matt Pauls to board of directors - Investing.com
Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors - The Globe and Mail
Palvella Therapeutics Appoints Accomplished Rare Disease - GlobeNewswire
Palvella Therapeutics stock hits 52-week high at 151.36 USD - Investing.com
Palvella Therapeutics stock hits 52-week high at 151.36 USD By Investing.com - Investing.com Nigeria
Palvella Therapeutics, Inc.(NasdaqGM: PVLA) dropped from Russell 3000E Index - marketscreener.com
Palvella Therapeutics, Inc.(NasdaqGM: PVLA) dropped from Russell Microcap Index - marketscreener.com
Palvella submits FDA NDA for QTORIN gel - grafa.com
Palvella submits first module of NDA for rare skin disease therapy - Investing.com
Palvella Therapeutics Submits First Rolling NDA Module for QTORIN Rapamycin in Microcystic Lymphatic Malformations - Quiver Quantitative
Palvella Therapeutics Submits First Module of Rolling New - GlobeNewswire
Palvella Therapeutics, Inc.(NasdaqGM:PVLA) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Palvella Therapeutics, Inc.(NasdaqGM: PVLA) dropped from Russell 3000 Value Benchmark - marketscreener.com
Palvella Therapeutics, Inc.(NasdaqGM: PVLA) dropped from Russell 2500 Value Benchmark - marketscreener.com
Palvella Therapeutics, Inc.(NasdaqGM:PVLA) dropped from Russell 3000E Value Benchmark - marketscreener.com
Palvella Therapeutics, Inc.(NasdaqGM:PVLA) dropped from Russell 3000E Growth Benchmark - marketscreener.com
What to Know About This $476,000 Palvella Therapeutics Insider Sale After a 620% Stock Rally - Yahoo Finance
What to Know About This $476,000 Palvella Therapeutics Insider Sale After a 620% Stock Rally - The Motley Fool
Price to earnings forward of Palvella Therapeutics, Inc. – NASDAQ:PVLA - TradingView
Palvella Therapeutics, Inc. Actuals & Estimates (NASDAQ:PVLA) - TradingView
Palvella Therapeutics Inc (PVLA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Palvella Therapeutics, Inc. Actuals & Estimates (LS:A40RA6) - TradingView
Canaccord reiterates Palvella stock rating on physician survey data - Investing.com UK
Enterprise value to revenue forward of Palvella Therapeutics, Inc. – LS:A40RA6 - TradingView
Enterprise value to EBIT forward of Palvella Therapeutics, Inc. – NASDAQ:PVLA - TradingView
A40RA6 Forecast — Price Target — Prediction for 2027 - TradingView
Palvella shares advance after FDA grants rolling review for rare disease therapy - MSN
Price to earnings forward of Palvella Therapeutics, Inc. – LS:A40RA6 - TradingView
Canaccord reiterates Palvella stock rating on physician survey data By Investing.com - Investing.com South Africa
Palvella Therapeutics Insiders Placed Bullish Bets Worth US$850.0k - Moomoo
CCORF Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $227 - Moomoo
Price to sales forward of Palvella Therapeutics, Inc. – NASDAQ:PVLA - TradingView
Price to book forward of Palvella Therapeutics, Inc. – LS:A40RA6 - TradingView
Enterprise value to EBITDA forward of Palvella Therapeutics, Inc. – LS:A40RA6 - TradingView
Stifel Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $250 - Moomoo
Craig-Hallum Reaffirms Their Buy Rating on Palvella Therapeutics (PVLA) - The Globe and Mail
Palvella Therapeutics COO Kathleen Goin sells $476,372 in stock By Investing.com - Investing.com India
Palvella stock rises on FDA rolling review for rare disease drug - Investing.com
Form 4 Palvella Therapeutics Inc For: 22 June By Investing.com - Investing.com Nigeria
Palvella Therapeutics COO Kathleen Goin sells $476,372 in stock - Investing.com
Palvella Therapeutics granted FDA rolling review for QTORIN - grafa.com
1.17%
2.48%
자본화:
|
볼륨(24시간):